Marksans Pharma has entered into a definitive agreement to acquire 100 percent of the share capital of QliniQ B.V., a profitable Netherlands-based pharmaceutical company with established front-end sales, marketing, and distribution capabilities across the Dutch healthcare market.

The acquisition marks a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union.

QliniQ operates a differentiated portfolio of niche pharmaceuticals and medical devices, with established positions across women’s health, dermatology, respiratory care, and other specialty categories. The company has developed long-standing relationships across wholesalers, pharmacies, hospitals and insurer-led tender channels in the Netherlands, supporting sustainable market access and growth. For the financial year ended December 31, 2025, QliniQ reported revenue of €9.35 million and net profit of €1.01 million. The company has delivered strong profitable growth, with revenue increasing at a CAGR of approximately 41 percent between FY2023 and FY2025, while maintaining a debt-free balance sheet.

Commenting on this acquisition, Albert de Bruin and Raymond Lansink, Board members and Shareholders, QliniQ BV said, "We are delighted that QliniQ is becoming part of the Marksans Group. During our discussions with Marksans, we were particularly impressed by the company’s strong track record in product development, its clear long-term vision, and its commitment to quality and innovation. Marksans has built strong product development capabilities, a broad and growing portfolio, and high-quality manufacturing expertise. Combining these strengths with QliniQ’s market presence and local expertise creates a compelling opportunity for future growth and value creation. Most importantly, we share a common ambition: to improve access to high-quality medicines and create long-term value for patients, healthcare providers, business partners, and employees. We are excited about the opportunities ahead and look forward to working closely with the Marksans team to build on our shared growth ambitions.”

The acquisition provides Marksans with established sales, marketing and distribution capabilities in the Netherlands, one of Europe’s key pharmaceutical markets; access to long-standing relationships with leading wholesalers, pharmacies, hospitals and health insurers; participation in insurer-led tender channels with visibility across multiple products and established relationships with leading Dutch health insurers; EU GDP-compliant warehousing, wholesale distribution and regulatory infrastructure; multiple routes to market through wholesalers, pharmacies and direct-to-consumer channels; and enhanced market access capabilities to support future portfolio expansion across Europe.

Commenting on the acquisition, Mark Saldanha, Chairman and Managing Director, Marksans Pharma, said, “This acquisition represents an important strategic step in expanding Marksans’ presence across regulated European markets. QliniQ has built a profitable niche portfolio supported by established market access capabilities, long-standing customer relationships, and tender participation across the Netherlands healthcare ecosystem. The acquisition provides Marksans with direct access to the Netherlands market and enhances our ability to commercialise existing and future products across regulated European markets. We believe this acquisition will strengthen our long-term growth opportunities and further enhance our global business.”

The acquisition is expected to support commercialisation of Marksans’ existing and future product portfolio in the Netherlands and strengthen its long-term presence across regulated European markets.